- organizations:Nanoscope Therapeutics
Pipeline
Nanoscope to submit optogenetic therapy BLA for RP
Company reports productive FDA meeting regarding MCO-010, plans for a Q1 2025 submission.
Pipeline
Nanoscope plans for phase 3 trial on Stargardt macular degeneration
Company reports productive end-of-phase 2 meeting with FDA regarding its gene therapy vector.
Pipeline
Nanoscope reports positive data from RESTORE trial on optogenetic therapy for RP
Statistical significance noted for MCO-010 in demonstrating clinically meaningful vision improvement for legally blind, advanced RP patients.
Pipeline
Nanoscope updates regulatory status of RP optogenetic therapy
FDA recommends primary efficacy endpoint to support an eventual BLA submission.
Business
Nanoscope names former Iveric Bio CEO as chairman of the board
Ophthalmic industry veteran Glenn Sblendorio joins the biotech company.
Pipeline
Nanoscope reports trial data on MCO-010 for Stargardt disease
Novel gene therapy demonstrates a favorable safety profile similar to findings from RP clinical studies.
Pipeline
Nanoscope releases key efficacy data from phase 2b trial for RP
Clinically significant vision improvement observed among patients treated with the optogenetic therapy MCO-010.
Pipeline
Positive topline results reported in optogenetic therapy trial for RP
Nanoscope Therapeutics’ phase 2b study assessed MCO-010 in restoring vision.
Archives